Loading organizations...
HLA Data Systems develops specialized software and interoperability solutions tailored for the histocompatibility and immunogenetics community. Its flagship product, mTilda, functions as a comprehensive Laboratory Information System (LIS), providing a single system of record for managing critical data. This Windows-based platform is designed to streamline operations by enabling robust report generation, efficient data retrieval, and secure data exchange within highly specialized laboratory environments.
The company was founded on the collective experience of a team with decades of expertise in implementing software solutions within clinical laboratories. This deep understanding of the unique data challenges and operational needs of histocompatibility and immunogenetics labs provided the foundational insight for creating purpose-built systems. This pedigree ensures their offerings are precisely aligned with the intricate requirements of their target users.
HLA Data Systems serves clinical laboratories that specialize in human leukocyte antigen (HLA) testing and related immunogenetics. The company's vision centers on advancing data excellence and interoperability within these critical medical fields, ensuring that laboratories can manage complex information with precision and efficiency. It aims to empower these labs with robust tools to support their vital diagnostic and research functions.
HLA Data Systems has raised $750K across 1 funding round.
HLA Data Systems has raised $750K in total across 1 funding round.
HLA Data Systems has raised $750K in total across 1 funding round.
HLA Data Systems's investors include Atlassian Ventures, Awesome People Ventures, Golden Section Ventures, Slack Fund, Stellar Capital, Wing Venture Capital, Michael Stoppelman.
HLA Data Systems has raised $750K across 1 funding round. Most recently, it raised $750K Series U in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2021 | $750K Series U | — | Atlassian Ventures, Awesome People Ventures, Golden Section Ventures, Slack Fund, Stellar Capital, Wing Venture Capital, Michael Stoppelman | Announced |
HLA Data Systems is a Houston-based technology company specializing in software solutions for histocompatibility and immunogenetics (H&I) laboratories, primarily offering mTilda, a comprehensive laboratory information management system (LIMS) for managing specimen workflows, patient data, inventory, and customizable reporting.[1][2][3][6] It serves H&I labs—critical for organ transplantation and transplant immunology—by solving challenges in data management, interoperability with electronic medical records (EMRs), and advanced analyses like virtual crossmatching and epitope matching through tools such as VxMatch, VECTR, NGSConnect, and EMR Integrate.[1][2][6] The company has demonstrated growth via VC funding, including $1M total raised (latest unattributed VC from investors like Golden Section/GSV), and recognition as the leading LIMS provider for HLA labs in the US, with a small team (1-10 employees) focused on domain expertise.[1][3]
Founded in 2000 in Houston, Texas, HLA Data Systems emerged to address specialized needs in H&I labs, building from deep domain knowledge in human leukocyte antigen (HLA) testing essential for transplant matching.[1][3][6] Key figures include Michael J. Reardon (CEO), Collin Brack (President), and Adam Day (CEO/CFO in some records), with the company evolving around its flagship mTilda LIMS, initially developed as a Windows-based solution for histocompatibility workflows.[3][4][7] A pivotal expansion occurred in 2016 when the team scaled operations to broaden mTilda's availability, incorporating customer support strengths and innovating for new techniques like epitope analysis and EMR integration amid growing data demands in healthcare.[2] Early traction stemmed from real-world lab challenges, positioning it as a market leader per investors like GSV's Dougal Cameron and Adam Day.[1]
HLA Data Systems rides the wave of precision medicine and transplant tech expansion, where rising organ transplants (over 40,000 annually in the US) demand advanced HLA typing, NGS sequencing, and epitope matching to reduce rejection risks.[1][2] Timing aligns with healthcare's digital shift—EMR mandates, big data analytics, and interoperability standards (e.g., FHIR)—amplifying needs for specialized LIMS in a niche but high-stakes $multi-billion transplant diagnostics market.[2][5] Favorable forces include post-pandemic transplant backlogs and AI-driven immunology tools; the company influences the ecosystem by standardizing H&I workflows, enabling labs to focus on clinical outcomes rather than data silos, and partnering with IT/EMR providers.[1][6]
HLA Data Systems is poised for expansion as transplant volumes grow and H&I labs adopt NGS/epitope tools; expect deeper AI integration for predictive matching, broader EMR compatibility, and potential acquisitions by larger healthtech players.[1][2] Trends like personalized immunogenetics and value-based care will propel demand, evolving its role from niche LIMS leader to essential interoperability hub in transplant ecosystems—building on its domain moat to capture more market share.[6] This positions it as a steady bet in medtech's data-driven future, humanizing complex HLA workflows for life-saving impact.
